Article · 26 Sep 2025
Conference abstractPublished 23 Sep 2013
Biosimilar in pharmerging markets
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Recently, the expiration of patents for a number of blockbuster biologics in EU and US has ushered in an era of the subsequent production of biosimilar products, which might contribute to increased access to these products at an affordable price. However, biopharma sales in these major markets will grow slowly during the next ten years and global pharmaceutical industry is turning to emerging markets such as China, India, Brazil, and Russia for growth and profitability. This presentation will review the patent protections of some blockbuster biologics in pharmerging markets and the potential advantages and obstacles of developing biosimilars in these emerging market.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Commentary · 30 Sep 2024
Exploring the Impact of Biosimilars on Biopharmaceutical Markets: Trends and Future Directions
Conference abstract · 30 Aug 2022
U.S. Biosimilars Market - A Deep Dive
Market analysis · 29 Jan 2021
Market Analysis- Biosimilars and Pharma Innovations, February 25-26, 2021, Webinar
Article · 2021
Market Analysis - World Biosimilars 2021
More from this journal
The newest in Journal of Bioanalysis & Biomedicine.
Article · 29 Dec 2025
Label-Free Biosensing: Revolutionizing Disease Detection and Drug Discovery
Article · 29 Dec 2025
Epigenetic Modifications: Bioanalysis for Disease and Therapeutics
Article · 29 Dec 2025
Advancing Bioanalysis: New Tech, AI, and Precision Medicine
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioanalysis & Biomedicine
- BylineArticles whose byline prints “Jun Wang”

